ATE180832T1 - Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie - Google Patents

Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie

Info

Publication number
ATE180832T1
ATE180832T1 AT96928205T AT96928205T ATE180832T1 AT E180832 T1 ATE180832 T1 AT E180832T1 AT 96928205 T AT96928205 T AT 96928205T AT 96928205 T AT96928205 T AT 96928205T AT E180832 T1 ATE180832 T1 AT E180832T1
Authority
AT
Austria
Prior art keywords
present
methods
adrenomedullin
physiology
peptides
Prior art date
Application number
AT96928205T
Other languages
German (de)
English (en)
Inventor
Frank Cuttitta
Alfredo Martinez
Mae Jean Miller
Edward J Unsworth
William Hook
Thomas Walsh
Karen Gray
Charles Macri
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Application granted granted Critical
Publication of ATE180832T1 publication Critical patent/ATE180832T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
AT96928205T 1995-08-18 1996-08-16 Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie ATE180832T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US251495P 1995-08-18 1995-08-18
US293695P 1995-08-30 1995-08-30
US1317296P 1996-03-12 1996-03-12

Publications (1)

Publication Number Publication Date
ATE180832T1 true ATE180832T1 (de) 1999-06-15

Family

ID=27357180

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96928205T ATE180832T1 (de) 1995-08-18 1996-08-16 Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie

Country Status (7)

Country Link
US (4) US6320022B1 (2)
EP (1) EP0845036B1 (2)
JP (2) JPH11512087A (2)
AT (1) ATE180832T1 (2)
CA (1) CA2229741C (2)
DE (1) DE69602756T2 (2)
WO (1) WO1997007214A1 (2)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6440421B1 (en) 1996-04-18 2002-08-27 Auchkland Uniservices Limited Treatment of bone disorders with adrenomedullin or adrenomedullin agonists
US5888963A (en) * 1996-04-18 1999-03-30 Auckland Uniservices Limited Treatment of bone disorders with adrenomedullin
AU9369098A (en) 1997-09-26 1999-04-23 Auckland Uniservices Limited Therapeutic method
PT1214600E (pt) * 1999-09-10 2006-05-31 Us Gov Health & Human Serv Determinacao de proteinas de ligacao a adrenomedulina
KR100486622B1 (ko) * 2000-11-17 2005-05-03 차국헌 폴리메틸실세스퀴옥산 공중합체와 그 제조방법 및 이를이용한 저유전성 코팅막
FR2821080B1 (fr) * 2001-02-20 2003-12-19 Sanofi Synthelabo Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques
US20110087312A1 (en) * 2001-03-02 2011-04-14 Erchonia Corporatin Method for Treatment of Diabetes and Prediabetes with Low-Level Laser Therapy
JP2005508838A (ja) 2001-03-23 2005-04-07 アフトン コーポレーション 膵癌の組合せ治療
US20090191232A1 (en) 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
AU2003221096A1 (en) * 2002-03-19 2003-09-29 Oncorex, Inc. Peptides, medicinal compositions containing the peptide and medicinal compositions for treating cancer
US20040127445A1 (en) * 2002-08-28 2004-07-01 Chondrogene Limited Beta-2 microglobulin (B2M) and B2M related gene products for the regulation of osteoarthritis pathogenesis and chondrocyte proliferation
CA2500405A1 (en) * 2002-09-30 2004-04-15 Oncotherapy Science, Inc. Genes and polypeptides relating to human myeloid leukemia
EP1575417A4 (en) * 2002-09-30 2007-07-04 Bayer Pharmaceuticals Corp CANCER FORECASTING AND PROGNOSTIC TECHNIQUES AND SURVEILLANCE OF ANTICANCER THERAPY
EP1545287B1 (en) 2002-10-04 2012-12-05 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, represented by THE DEPARTMENT OF HEALTH & HUMAN SERVICES Vasoregulating compounds and methods of their use
JP5068428B2 (ja) * 2002-11-07 2012-11-07 アメリカ合衆国 血管新生および抗血管新生療法のための標的
JP4689597B2 (ja) * 2003-03-28 2011-05-25 レセプター バイオロジックス インク． ガストリンホルモン免疫アッセイ
US7228658B2 (en) 2003-08-27 2007-06-12 Weyerhaeuser Company Method of attaching an end seal to manufactured seeds
US20080249115A1 (en) * 2003-09-08 2008-10-09 The Government Of The United States Of America, As Non Peptide Agonists and Antagonists of Adrenomedullin and Gastric Releasing Peptide
US8691575B2 (en) * 2003-09-30 2014-04-08 Weyerhaeuser Nr Company General method of classifying plant embryos using a generalized Lorenz-Bayes classifier
US20050108935A1 (en) * 2003-11-25 2005-05-26 Edwin Hirahara Method and system of manufacturing artificial seed coats
US7555865B2 (en) * 2003-11-25 2009-07-07 Weyerhaeuser Nr Company Method and system of manufacturing artificial seed coats
CA2484533C (en) * 2003-11-25 2008-12-02 Weyerhaeuser Company Systems and method of embryo delivery for manufactured seeds
US20050108929A1 (en) * 2003-11-25 2005-05-26 Edwin Hirahara Method and system for creating manufactured seeds
CA2486289C (en) * 2003-11-25 2008-01-08 Weyerhaeuser Company Combination end seal and restraint
US7356965B2 (en) * 2003-12-11 2008-04-15 Weyerhaeuser Co. Multi-embryo manufactured seed
US7591287B2 (en) * 2003-12-18 2009-09-22 Weyerhaeuser Nr Company System and method for filling a seedcoat with a liquid to a selected level
US7568309B2 (en) * 2004-06-30 2009-08-04 Weyerhaeuser Nr Company Method and system for producing manufactured seeds
KR101333168B1 (ko) 2004-09-22 2013-11-28 리셉터 바이오로직스 인크 프로가스트린에 대한 모노클로날 항체
US20060070145A1 (en) * 2004-09-27 2006-03-30 Carlson William C Manufactured seed having a live end seal
US20060064930A1 (en) * 2004-09-27 2006-03-30 Carlson William C Manufactured seed having a live end seal coating
US7547488B2 (en) * 2004-12-15 2009-06-16 Weyerhaeuser Nr Company Oriented strand board panel having improved strand alignment and a method for making the same
US7654037B2 (en) * 2005-06-30 2010-02-02 Weyerhaeuser Nr Company Method to improve plant somatic embryo germination from manufactured seed
US8168592B2 (en) 2005-10-21 2012-05-01 Amgen Inc. CGRP peptide antagonists and conjugates
US9829494B2 (en) * 2005-12-01 2017-11-28 Adrenomed Ag Methods of treatment using ADM antibodies
US8906857B2 (en) * 2005-12-01 2014-12-09 B.R.A.H.M.S. Gmbh Methods for the diagnosis and treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
DE102006052916A1 (de) * 2006-11-08 2008-05-15 Brahms Aktiengesellschaft Diagnose und Risikostratifizierung von Diabetes mellitus mittels MR-proADM
EP2190533A2 (en) * 2007-09-11 2010-06-02 Mondobiotech Laboratories AG Use of a peptide as a therapeutic agent
FR2934597B1 (fr) * 2008-07-31 2013-04-19 Univ Aix Marseille Ii Anticorps se liant aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament.
WO2010049180A1 (en) * 2008-10-31 2010-05-06 B.R.A.H.M.S. Ag Methods and assays for classifying foodstuff and/or beverage and/or diet and/or nutrition regimen and/or medicament in view of an effect on the cardiovascular system
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
EP2389799A1 (en) * 2010-05-25 2011-11-30 BioMass Booster, S.L. Method for increasing plant biomass
CN103109192A (zh) * 2010-06-18 2013-05-15 塞尚公司 用于妊娠性高血压和先兆子痫的预后和风险评估的标志物
FR2964103B1 (fr) * 2010-08-30 2018-11-23 Universite D'aix-Marseille Anticorps se liant a l'adrenomedulline et aux recepteurs de l'adrenomedulline et leurs utilisations comme medicament
JP5932279B2 (ja) * 2011-10-07 2016-06-08 ポーラ化成工業株式会社 スクリーニング方法
US8776012B2 (en) * 2011-10-25 2014-07-08 International Business Machines Corporation Automatic scheduling of review meetings
EP2780370B1 (en) 2011-11-16 2019-09-25 AdrenoMed AG Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation
EP4086283A1 (en) 2011-11-16 2022-11-09 AdrenoMed AG Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for prevention or reduction of organ dysfunction or organ failure in a patient having a chronic or acute disease or acute condition
DK2780717T3 (en) 2011-11-16 2017-02-13 Sphingotec Gmbh ADRENOMEDULLINASSAYS AND METHODS FOR DETERMINING MODERN ADRENOMEDULLIN
DK2780371T3 (en) 2011-11-16 2019-02-25 Adrenomed Ag ANTI-ADDRENOMEDULLIN (ADM) ANTIBODY OR ANTI-ADM ANTISTOFFRAGMENT OR ANTI-ADM NON-IG TEMPLATE FOR REGULATING LIQUID BALANCE OF A PATIENT WITH A CHRONIC OR ACUTE DISEASE
JP5953108B2 (ja) * 2012-05-14 2016-07-20 ポーラ化成工業株式会社 スクリーニング方法
EP2905029B1 (en) 2012-10-04 2018-11-21 Shionogi&Co., Ltd. Drug for inhibiting malignant tumor metastasis
WO2015092021A1 (en) * 2013-12-20 2015-06-25 Spingotec Therapeutics Gmbh Adrenomedullin binder for use in therapy of cancer
PT3067093T (pt) * 2015-03-12 2019-11-18 Fund Rioja Salud Utilização de um inibidor de adrenomedulina para a produção de um fármaco útil na prevenção e tratamento de doenças que reduzem a densidade óssea
CA3064962A1 (en) 2017-05-26 2018-11-29 National Research Council Of Canada Self-assembling peptide for activating human mast cells
WO2018232230A1 (en) 2017-06-15 2018-12-20 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
US12150978B2 (en) 2017-06-15 2024-11-26 Cancer Advances Inc. Compositions and methods for preventing tumors and cancer
EP3438668A1 (en) * 2017-08-04 2019-02-06 B.R.A.H.M.S GmbH Diagnosis and risk stratification of fungal infections
EP3971572A1 (en) 2017-09-13 2022-03-23 B.R.A.H.M.S GmbH Proadrenomedullin as a marker for abnormal platelet levels
WO2019053116A1 (en) 2017-09-13 2019-03-21 B.R.A.H.M.S Gmbh FLUID THERAPY GUIDING METHOD BASED ON PROADRENOMEDULLINE
EP3502706A1 (en) 2017-12-20 2019-06-26 B.R.A.H.M.S GmbH Workflow for risk assessment and patient management using procalcitonin and midregional-proadrenomedullin
EP3578989A1 (en) 2018-06-06 2019-12-11 B.R.A.H.M.S GmbH Pro-adm for prognosis of trauma-related complications in polytrauma patients
CN115175920B (zh) 2019-11-13 2025-10-31 阿穆尼克斯制药公司 加条形码的xten多肽及其组合物以及其制备和使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1306095A3 (en) * 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
WO1994025482A1 (en) * 1993-04-23 1994-11-10 Evans Herbert J Polypeptides that include conformation-constraining groups which flank a protein-protein interaction site
JP2774769B2 (ja) * 1993-04-26 1998-07-09 賢治 寒川 アドレノメデュリン

Also Published As

Publication number Publication date
EP0845036B1 (en) 1999-06-02
US6320022B1 (en) 2001-11-20
JPH11512087A (ja) 1999-10-19
US7622272B2 (en) 2009-11-24
JP4077861B2 (ja) 2008-04-23
AU710662B2 (en) 1999-09-23
US20100021469A1 (en) 2010-01-28
WO1997007214A1 (en) 1997-02-27
CA2229741A1 (en) 1997-02-27
US7101548B2 (en) 2006-09-05
JP2007145850A (ja) 2007-06-14
DE69602756D1 (de) 1999-07-08
DE69602756T2 (de) 2000-02-10
US20020055615A1 (en) 2002-05-09
US7939639B2 (en) 2011-05-10
EP0845036A1 (en) 1998-06-03
AU6776596A (en) 1997-03-12
US20070004630A1 (en) 2007-01-04
CA2229741C (en) 2012-05-08

Similar Documents

Publication Publication Date Title
ATE180832T1 (de) Funktionelle rolle von adrenomedullin(am) und dem gen-verwandten produkt(pamp) in der menschlichen pathologie und physiologie
Nilsson et al. Staudinger ligation: a peptide from a thioester and azide
Baluna et al. Evidence for a structural motif in toxins and interleukin-2 that may be responsible for binding to endothelial cells and initiating vascular leak syndrome
RU2362780C2 (ru) Nogo-a-нейтрализующие иммуноглобулины для лечения неврологических заболеваний
ATE267607T1 (de) Verwendung von löslichen oligomerischen cd40 liganden oder monoklonalen antikörpern zur herstellung eines arzneimitells zur vorbeugung oder behandlung von neoplastischen krankheiten
UA29494C2 (uk) Гуманізовані антитіла, способи їх продукування, спосіб лікування хвороби крона, спосіб лікування розсіяного склерозу, фармацевтична композиція
Bleuez et al. Exploiting protease activation for therapy
ATE445641T1 (de) Glucagon ähnliche peptide-2 und ihre therapeutische verwendung
AR003087A1 (es) PROTEINAS OBESAS RECOMBINANTES (Oh), VECTOR DE EXPRESION, PROTEINA DE FUSION, SECUENCIA DE ADN, METODO PARA PRODUCIR DICHAS PROTEINAS, COMPOSICIONQUE LAS COMPRENDE, EMPLEO DE DICHAS PROTEINAS Y METODO DE TRATAMIENTO.
YU46097A (sh) Nova klasa estara i njihove farmaceutske smeše
DE69836139D1 (de) Verfahren zur behandlung von vaskulären proliferativen erkrankungen mit p27 und fusionen davon
RU94016384A (ru) Лизосомные расщепляемые ферментами противоопухолевые лекарственные коньюгаты
ATE332702T1 (de) Verwendung von glu-trp dipeptiden zur herstellung eines arzneimittels zur behandlung von verschiedenen gefässneubildung-assozierten erkrankungen
ATE306473T1 (de) Neue piperazinyl-substituierte pyridylalkan, alken and alkin carboxamide
HRP20020787B1 (hr) Postupak liječenja upotrebom kompleksa ligand-imunogen
NZ504549A (en) Use of a modified non-toxic botulinum toxin for delivery of medicines where non-toxicity results from modification of light chain holotoxin to eliminate zinc-dependant metalloendoprotease without modification to the heavy chain portion essential for translocation activity from the gut to the lumen
ES2074042T3 (es) Exotoxina recombinante de pseudomonas construccion de una inmunotoxina activa con efectos secundarios menores.
CZ20004161A3 (cs) Hybridní protein pro zabránění granulace žírných buněk a jeho použití
DE69425246D1 (de) Monoklonale antikoerper gegen lfa-1 zur herstellung eines arzneimittels zur vorbeugung der transplantatabstossung von organen
DE59303365D1 (de) Derivate in der vitamin d-reihe mit modifikationen in der 20 position, verfahren zu ihrer herstellung, zwischenprodukte für dieses verfahren, diese derivate enthaltende pharmazeutische präparate sowie deren verwendung zur herstellung von arzneimitteln
WO1999016791A3 (en) Compounds and methods for regulating cell adhesion
DE69228997D1 (de) Menschliche il-3-varianten
DE59610251D1 (de) Konjugat, umfassend einen wirkstoff, ein polypeptid und einen polyether
NO922621D0 (no) Farmasoeytiske preparater inneholdende antigen-antistoffkomplekser og anvendelser derav
Penna et al. Antitumor× anti-CD3 bifunctional antibodies redirect T-cells activated in vivo with staphylococcal enterotoxin B to neutralize pulmonary metastases

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties